1. WHO. Global Cancer Observatory. Available from: [Last accessed on 30 Mar 2020].

2. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.

3. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.

4. Yu ML, Huang CF, Yeh ML, Tsai PC, Huang CI, et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis c virus patients: a model for prioritization of treatment. Clin Cancer Res 2017;23:1690-7.

5. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, et al. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open 2019;9:e026703.

6. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int 2019;13:587-98.

7. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017:S0168-8278(17)32273-0.

8. Huang CF, Yu ML. Direct-acting antivirals response in hepatocellular carcinoma: does the presence of hepatocellular carcinoma matter? Clin Mol Hepatol 2019;25:168-71.

9. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85.

10. Saberi B, Dadabhai AS, Durand CM, Philosophe B, Cameron AM, et al. Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. Hepatology 2017;66:661-3.

11. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-92.

12. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461-511.

13. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 2016;10:681-701.

14. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.

15. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011;52:133-7.

16. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.

17. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.

18. Lin YH, Yeh ML, Huang CI, Yang JF, Liang PC, et al. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. Kaohsiung J Med Sci 2016;32:362-6.

19. Wang CC, Liu CH, Lin CL, Wang PC, Tseng TC, et al. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. J Formos Med Assoc 2015;114:923-8.

20. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.

21. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93.

22. Dai CY, Yeh ML, Huang JF, Chuang WL, Yu ML. Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. Hepatology 2011;53:1399.

23. Huang JF, Yu ML, Huang CF, Chiu CF, Dai CY, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. J Hepatol 2011;54:219-26.

24. Dai CY, Chen DS, Chen PJ, Kao JH, Liu CJ, et al. National registration database for the first year (2017) national health insurance reimbursed direct antiviral agents therapy for chronic hepatitis C in Taiwan. Hepatology 2018;68:403A.

25. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010;8:192-9.

26. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Int Med 2013;158:329-37.

27. Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of direct acting antivirals on survival in patients with chronic hepatitis C and hepatocellular carcinoma. Sci Rep 2019;9:17081.

28. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, et al. . Epub ahead of print. doi: 10.1002/hep.30988

29. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.

30. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017;66:1173-81.

31. Radhakrishnan K, Di Bisceglie AM, Reddy KR. Treatment status of hepatocellular carcinoma does not influence rates of sustained virologic response: an HCV-TARGET analysis. Hepatol Commun 2019;3:1388-99.

32. Ji F, Yeo YH, Wei MT, Wei B, Dang S, et al. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter? Hepatology 2018;67:1180-2.

33. Niu J, Kumar U, Monjardino J, Goldin R, Rosin D, et al. Hepatitis C virus replication in hepatocellular carcinoma. J Clin Pathol 1995;48:880-2.

34. Konjeti VR, John BV. Interaction between hepatocellular carcinoma and hepatitis C eradication with direct-acting antiviral therapy. Curr Treat Options Gastroenterol 2018;16:203-14.

35. Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol 2015;7:2080-90.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: